101 related articles for article (PubMed ID: 16482527)
1. Expression of BAG-1 protein correlates with aggressive behavior of prostate cancers.
Krajewska M; Turner BC; Shabaik A; Krajewski S; Reed JC
Prostate; 2006 Jun; 66(8):801-10. PubMed ID: 16482527
[TBL] [Abstract][Full Text] [Related]
2. Overexpression and gene amplification of BAG-1L in hormone-refractory prostate cancer.
Mäki HE; Saramäki OR; Shatkina L; Martikainen PM; Tammela TL; van Weerden WM; Vessella RL; Cato AC; Visakorpi T
J Pathol; 2007 Aug; 212(4):395-401. PubMed ID: 17503439
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical expression of Hsp60 correlates with tumor progression and hormone resistance in prostate cancer.
Castilla C; Congregado B; Conde JM; Medina R; Torrubia FJ; Japón MA; Sáez C
Urology; 2010 Oct; 76(4):1017.e1-6. PubMed ID: 20708221
[TBL] [Abstract][Full Text] [Related]
4. Up-regulation of insulin-like growth factor axis components in human primary prostate cancer correlates with tumor grade.
Liao Y; Abel U; Grobholz R; Hermani A; Trojan L; Angel P; Mayer D
Hum Pathol; 2005 Nov; 36(11):1186-96. PubMed ID: 16260272
[TBL] [Abstract][Full Text] [Related]
5. External beam radiotherapy (EBRT) suppressed prostate stem cell antigen (PSCA) mRNA expression in clinically localized prostate cancer.
Zhigang Z; Wenlu S
Prostate; 2007 May; 67(6):653-60. PubMed ID: 17342746
[TBL] [Abstract][Full Text] [Related]
6. Expression and clinical role of antiapoptotic proteins of the bag, heat shock, and Bcl-2 families in effusions, primary tumors, and solid metastases in ovarian carcinoma.
Elstrand MB; Kleinberg L; Kohn EC; Tropé CG; Davidson B
Int J Gynecol Pathol; 2009 May; 28(3):211-21. PubMed ID: 19620938
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of SIM2-s protein is a novel marker of aggressive prostate cancer.
Halvorsen OJ; Rostad K; Øyan AM; Puntervoll H; Bø TH; Stordrange L; Olsen S; Haukaas SA; Hood L; Jonassen I; Kalland KH; Akslen LA
Clin Cancer Res; 2007 Feb; 13(3):892-7. PubMed ID: 17289882
[TBL] [Abstract][Full Text] [Related]
8. Fascin regulates prostate cancer cell invasion and is associated with metastasis and biochemical failure in prostate cancer.
Darnel AD; Behmoaram E; Vollmer RT; Corcos J; Bijian K; Sircar K; Su J; Jiao J; Alaoui-Jamali MA; Bismar TA
Clin Cancer Res; 2009 Feb; 15(4):1376-83. PubMed ID: 19228738
[TBL] [Abstract][Full Text] [Related]
9. Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers.
Sun A; Tawfik O; Gayed B; Thrasher JB; Hoestje S; Li C; Li B
Prostate; 2007 Feb; 67(2):203-13. PubMed ID: 17075831
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
Okegawa T; Kinjo M; Nutahara K; Higashihara E
Int J Urol; 2006 Sep; 13(9):1197-201. PubMed ID: 16984552
[TBL] [Abstract][Full Text] [Related]
11. The potential role of purine-rich element binding protein (PUR) alpha as a novel treatment target for hormone-refractory prostate cancer.
Inoue T; Leman ES; Yeater DB; Getzenberg RH
Prostate; 2008 Jul; 68(10):1048-56. PubMed ID: 18386260
[TBL] [Abstract][Full Text] [Related]
12. [NFkappaB : a new marker kappable of predicting prostate cancer outcome].
Lessard L; Mes-Masson AM; Saad F
Bull Cancer; 2006 Sep; 93(9):891-9. PubMed ID: 16980232
[TBL] [Abstract][Full Text] [Related]
13. The significance of LMO2 expression in the progression of prostate cancer.
Ma S; Guan XY; Beh PS; Wong KY; Chan YP; Yuen HF; Vielkind J; Chan KW
J Pathol; 2007 Feb; 211(3):278-85. PubMed ID: 17167821
[TBL] [Abstract][Full Text] [Related]
14. Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer.
Horvath LG; Lelliott JE; Kench JG; Lee CS; Williams ED; Saunders DN; Grygiel JJ; Sutherland RL; Henshall SM
Prostate; 2007 Jul; 67(10):1081-90. PubMed ID: 17476687
[TBL] [Abstract][Full Text] [Related]
15. Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer.
Davis JN; Wojno KJ; Daignault S; Hofer MD; Kuefer R; Rubin MA; Day ML
Cancer Res; 2006 Dec; 66(24):11897-906. PubMed ID: 17178887
[TBL] [Abstract][Full Text] [Related]
16. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy.
Henshall SM; Horvath LG; Quinn DI; Eggleton SA; Grygiel JJ; Stricker PD; Biankin AV; Kench JG; Sutherland RL
J Natl Cancer Inst; 2006 Oct; 98(19):1420-4. PubMed ID: 17018789
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of E-cadherin and ezrin immunohistochemical expression in prostate cancer.
Musiał J; Sporny S; Nowicki A
Pol J Pathol; 2007; 58(4):235-43. PubMed ID: 18459457
[TBL] [Abstract][Full Text] [Related]
18. hCAP-D3 expression marks a prostate cancer subtype with favorable clinical behavior and androgen signaling signature.
Lapointe J; Malhotra S; Higgins JP; Bair E; Thompson M; Salari K; Giacomini CP; Ferrari M; Montgomery K; Tibshirani R; van de Rijn M; Brooks JD; Pollack JR
Am J Surg Pathol; 2008 Feb; 32(2):205-9. PubMed ID: 18223322
[TBL] [Abstract][Full Text] [Related]
19. The importance of determining the aggressiveness of prostate cancer using serum and tissue molecular markers.
Kehinde EO; Maghrebi MA; Anim JT
Can J Urol; 2008 Apr; 15(2):3967-74. PubMed ID: 18405443
[TBL] [Abstract][Full Text] [Related]
20. The cytoskeleton differentially localizes the early growth response gene-1 protein in cancer and benign cells of the prostate.
Mora GR; Olivier KR; Cheville JC; Mitchell RF; Lingle WL; Tindall DJ
Mol Cancer Res; 2004 Feb; 2(2):115-28. PubMed ID: 14985468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
